This review aims to analyse the efficacy of dietary supplements in reducing plasma cholesterol levels. Focusing on evidence from meta-analyses of randomised controlled clinical trials, with an emphasis on potential mechanisms of action as supported by human, animal, and cell studies. Certain dietary supplements including phytosterols, berberine, viscous soluble dietary fibres, garlic supplements, soy protein, specific probiotic strains, and certain polyphenol extracts could significantly reduce plasma total and low-density lipoprotein (LDL) cholesterol levels by 3-25% in hypercholesterolemic patients depending on the type of supplement. They tended to be more effective in reducing plasma LDL cholesterol level in hypercholesterolemic individuals than in normocholesterolemic individuals. These supplements worked by various mechanisms, such as enhancing the excretion of bile acids, inhibiting the absorption of cholesterol in the intestines, increasing the expression of hepatic LDL receptors, suppressing the activity of enzymes involved in cholesterol synthesis, and activating the adenosine monophosphate-activated protein kinase signalling pathway.
Keyphrases
- low density lipoprotein
- clinical trial
- signaling pathway
- protein kinase
- end stage renal disease
- endothelial cells
- systematic review
- newly diagnosed
- chronic kidney disease
- ejection fraction
- escherichia coli
- meta analyses
- poor prognosis
- randomized controlled trial
- stem cells
- single cell
- study protocol
- cell therapy
- risk assessment
- prognostic factors
- induced pluripotent stem cells
- open label